BELL therapeutics
Uses innovative biotechnology to develop next-generation treatments that are more customized, accessible, and effective.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Based in Seoul, South Korea, BELL Therapeutics is a digital therapeutics (DTx) firm established in 2023. The company operates in the digital health sector, focusing on developing software-based treatments for medical conditions that are prescribed by doctors. Its revenue model is centered on the development and sale of these clinically-proven software as a medical device (SaMD) solutions.
The company was founded by a team that includes CEO Jae-eun Lee, a Columbia University economics graduate, alongside experts in neuroscience, auditory science, and AI engineering. This diverse expertise underpins the company's approach to creating its therapeutic products. Since its inception, BELL Therapeutics has secured seed funding from investors such as FuturePlay, HGI, and the Korea SMEs and Startups Agency in September 2023. Further investment was received from Naver's venture capital arm, Spring Camp, in June 2024. A significant milestone was achieved in October 2024 when the company was selected for the 'Deep Tech TIPS' program, securing up to KRW 1.7 billion for research and development.
BELL Therapeutics' product pipeline is built on its proprietary neuroengineering-integrated audio signal processing technology. The company is developing two main products. The first, "Bell-001 Sleep Thera," is a digital therapeutic for insomnia that provides real-time biofeedback sounds based on the patient's biological signals, with clinical trials showing immediate effects. The second product, "Bell-002 Wowfit," is designed for auditory rehabilitation for cochlear implant users, aiming to significantly shorten the typical post-surgery rehabilitation period. Unlike wellness apps, these digital therapeutics require a doctor's prescription, highlighting their clinical nature and a business model geared towards integration with the healthcare system.
Keywords: digital therapeutics, DTx, SaMD, neuroengineering, auditory rehabilitation, insomnia treatment, cochlear implants, biofeedback, software as a medical device, digital health, South Korean startup, Jae-eun Lee, Sleep Thera, Wowfit, neuro-therapeutics, audio signal processing, clinical software, prescription digital therapeutics, healthcare technology, sleep science